ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2009
Antiangiogenic strategies for treatment of malignant gliomas.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma.Journal of neuro-oncology · 2016Trial
- Molecular targeting of glioblastoma: Drug discovery and therapies.Trends in molecular medicine · 2011Trial
- The strange Microenvironment of Glioblastoma.Revue neurologique · 2023Review
- Postoperative resveratrol administration improves prognosis of rat orthotopic glioblastomas.BMC cancer · 2018Article
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.Science translational medicine · 2017Article
- Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.Science translational medicine · 2015Article
- Update on anti-angiogenic treatment for malignant gliomas.Current oncology reports · 2014Review
- Subcurative radiation significantly increases cell proliferation, invasion, and migration of primary glioblastoma multiforme in vivo.Chinese journal of cancer · 2014Article
- Article
- Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2.Cold Spring Harbor perspectives in medicine · 2012Review
- Glioblastoma multiforme: novel therapeutic approaches.ISRN neurology · 2012Article
- Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas.Journal of oncology · 2012Article
- Towards personalized therapy for patients with glioblastoma.Expert review of anticancer therapy · 2011Review
- Genetics of glioblastoma: a window into its imaging and histopathologic variability.Radiographics : a review publication of the Radiological Society of North America, Inc · 2011Review
- Aberrant signaling pathways in glioma.Cancers · 2011Article
- Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach.Proteome science · 2011Article
- Inhibition of brain tumor growth by intravenous poly (β-L-malic acid) nanobioconjugate with pH-dependent drug release [corrected].Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Antiangiogenic therapies for high-grade glioma.Nature reviews. Neurology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous antiangiogenic agents with diverse mechanisms of action are currently under investigation for the treatment of patients with glioblastoma (GBM), a diagnosis that continues to carry a poor prognosis despite maximal conventional therapy. Early clinical trials suggest that antiangiogenic drugs, which target the blood vessels of these highly angiogenic tumors, may have clinical benefit in GBM patients. Antiangiogenic agents have potent antiedema and steroid-sparing effects in patients, and emerging data suggest that these drugs may modestly improve progression-free survival. Although these early results are encouraging, several issues arise regarding the use and efficacy of these agents. Interpretation of the radiographic changes that occur after treatment with antiangiogenic agents presents a major challenge. Still lacking are reliable radiographic and biologic markers that can predict which patients will benefit from treatment and that accurately indicate response and progression during therapy. In addition, most patients treated with antiangiogenic drugs eventually progress, and the mechanisms by which tumors escape from therapy are only beginning to be understood. Larger prospective trials that incorporate correlative biomarker studies will be required to address these challenges. Here, we summarize the clinical experience with antiangiogenic therapy in patients with malignant gliomas (MG), review the major issues concerning the use and development of these agents, and discuss strategies that may build upon the initial gains observed with antiangiogenic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.